Design and Preparation of Potent, Nonpeptidic, Bioavailable Renin InhibitorsBezencon, O., Bur, D., Weller, T., Richard-Bildstein, S., Remen, L., Sifferlen, T., Corminboeuf, O., Grisostomi, C., Boss, C., Prade, L., Delahaye, S., Treiber, A., Strickner, P., Binkert, C., Hess, P., Steiner, B., Fischli, W.
(2009) J Med Chem 52: 3689-3702
- PubMed: 19358611
- DOI: https://doi.org/10.1021/jm900022f
- Primary Citation of Related Structures:
3G6Z, 3G70, 3G72
- PubMed Abstract:
Starting from known piperidine renin inhibitors, a new series of 3,9-diazabicyclo[3.3.1]nonene derivatives was rationally designed and prepared. Optimization of the positions 3, 6, and 7 of the diazabicyclonene template led to potent renin inhibitors. The substituents attached at the positions 6 and 7 were essential for the binding affinity of these compounds for renin. The introduction of a substituent attached at the position 3 did not modify the binding affinity but allowed the modulation of the ADME properties. Our efforts led to the discovery of compound (+)-26g that inhibits renin with an IC(50) of 0.20 nM in buffer and 19 nM in plasma. The pharmacokinetics properties of this and other similar compounds are discussed. Compound (+)-26g is well absorbed in rats and efficacious at 10 mg/kg in vivo.
Drug Discovery and Preclinical Research, Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland. email@example.com